Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to …
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to …
BEVERLY, MA–(Marketwire – 07/07/10) – Cellceutix Corporation (OTC.BB: CTIX – News ) today announced that it has completed all three animal safety pharmacology studies for its cancer compound, Kevetrin, that are required by the U. S. Food and Drug Administration prior to filing an IND. These studies involve assessments of the impact of the administration of a compound on the respiratory …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: animal, cancer, Cellceutix, Completes, compound, Pharmacology, prior, required, Safety, Studies, three
Cellceutix Completes Successful Pre-IND Meeting With FDA For Cancer Drug
Cellceutix Completes Successful Pre-IND Meeting With FDA For Cancer Drug
Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, announced that is has completed a successful pre-Investigational New Drug exemption (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound, Kevetrin, which is being developed to treat drug resistant cancers. The Company has …
Read more on Medical News Today
Categories: Breast Cancer Staging Tags: cancer, Cellceutix, Completes, drug, Meeting, PreIND, Successful